

Proteomics Facility

Service Request Form

University of Iowa, Carver College of Medicine

363 Eckstein Medical Research Building

Ph: 319-335-7956

>>>>

As the complexity of a sample increases, the risks of under-sampling are magnified. The risk rises faster for minor components, so the fidelity for trace level characterization tends to improve with affinity enrichment and often fractionation. Please raise the issue if you are concerned.

Last Name _____	First Name _____	MI _____
Lab Phone _____	Email _____	Your direct No. _____
Department _____	Advisor _____	Date _____

Note: Protein mixtures must be resolved in commercial Bis/TRIS or Tricine PAGE gels and stained with Coomassie (preferable) or "MS-compatible" Silver protocols. Please use; 1) *Coomassie*: Pierce Gel Code Blue or 2) *Silver*: Pierce Ag Stain kit for Mass Spectrometry (develop < 9 min.). Use "aseptic" precautions to avoid keratins and be advised that Ag staining increases the risks of keratin contamination. Beta mercaptoethanol (BME) in Laemmli buffer may be a source of keratin, use DTT instead. [Keratin advise](#) .

Sample Information	User Input	Complete on the reverse side if necessary
Project Name	The Sample originates from _____	Taxonomy is _____
<input type="checkbox"/> TAP <input type="checkbox"/> immunoaffinity Other: <input type="checkbox"/> Peptide Glycan	My Bait Protein is _____ <input type="checkbox"/> Lipid <input type="checkbox"/> Oligonucleotides	Expr'd in cell line? _____ Purified with? _____ Affinity support
Buffer composition?	Need mass of Intact oligomer? <input type="checkbox"/> <input type="checkbox"/> MALDI <input type="checkbox"/> nESI <input type="checkbox"/> Conc _____	Is the sample in a PAGE gel? _____ Manfact? _____ Ladder Set _____ %T _____ MW range _____ -- _____
What do you know about the sample(s) now?		
What would you like to learn?		
Other Comments		

MFK

FUND	ORG	DEPT	SUBDEPT	GRANT/PRGM	INST ACCT	ORG ACCT	DEPT AQCT	FN	CST CTR
XXX	XX	XXXX	XXXXX	XXXXX XX	XXXX	XXX	XXXXX	XX	XXXX

Analysis Method	Core input	This section will be filled in during consultation or analysis
Enrichment? <input type="checkbox"/> C ₁₈ <input type="checkbox"/> TiO ₂	<input type="checkbox"/> IMAC <input type="checkbox"/> SCX	<input type="checkbox"/> Other: _____ <input type="checkbox"/> in gel digest(s) <input type="checkbox"/> Depletion: _____
<input type="checkbox"/> MALDI-TOF	<input type="checkbox"/> Require Sequence of m/z _____	<input type="checkbox"/> Identify Adducts? _____
<input type="checkbox"/> ESI (infusion): <input type="checkbox"/> pos <input type="checkbox"/> neg	Require Sequence of: _____	<input type="checkbox"/> Identify Adducts?
<input type="checkbox"/> Off Gel Protein Fract? <input type="checkbox"/> direct digest <input type="checkbox"/> Enzyme? _____ <input type="checkbox"/> BioTyper? _____	<input type="checkbox"/> LC-ESI-MS/MS <input type="checkbox"/> LTQ XL <input type="checkbox"/> q/TOF <input type="checkbox"/> 3Quad <input type="checkbox"/> 1 st Column _____ <input type="checkbox"/> 2 nd Column _____	<input type="checkbox"/> gel-separated proteins <input type="checkbox"/> preferred ion list? <input type="checkbox"/> Exclude <input type="checkbox"/> Gradient _____ <input type="checkbox"/> Characterize PTM* <input type="checkbox"/> 3Q PreCur Which PTM? <input type="checkbox"/> 3Q NI loss <input type="checkbox"/> 3Q Product
Biomarker Discovery	<input type="checkbox"/> MudPit*	<input type="checkbox"/> LTQ XL <input type="checkbox"/> q/TOF <input type="checkbox"/> 3Q 1 st Dim. _____ # Steps _____
<input type="checkbox"/> Targeted Quantification* AQUA (long development)	<input type="checkbox"/> SILAC AA label(s): _____	<input type="checkbox"/> Chemical Labeling: <input type="checkbox"/> diMethyl <input type="checkbox"/> Label-free <input type="checkbox"/> iTRAQ, <input type="checkbox"/> O ₁₈ ,

*MudPit, PTM and quantification require advance consultation. **Extensive user projects may be charged for traps or columns.

Analyst _____ Instrument _____ Filename _____ Comments _____